Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide - PubMed (original) (raw)
. 2010 Jul 1;145(1):17-25.
doi: 10.1016/j.jconrel.2010.03.007. Epub 2010 Mar 20.
Xianhuo Wang, Yongsheng Wang, Li Yang, Jia Hu, Wenjing Xiao, Afu Fu, Lulu Cai, Xia Li, Xia Ye, Yalin Liu, Wenshuang Wu, Ximing Shao, Yongqiu Mao, Yuquan Wei, Lijuan Chen
Affiliations
- PMID: 20307599
- DOI: 10.1016/j.jconrel.2010.03.007
Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide
Xiang Chen et al. J Control Release. 2010.
Abstract
Fibroblast growth factor receptors (FGFRs), overexpressed on the surface of a variety of tumor cells and on tumor neovasculature in situ, are potential targets for tumor- and vascular-targeting therapy. This study aimed to develop a FGFR-mediated drug delivery system to target chemotherapeutic agents to FGFR-overexpressed tumor cells and tumor neovasculature endothelial cells in vitro and in vivo. Here we designed a truncated human basic fibroblast growth factor peptide (tbFGF), which was attached to the surface of cationic liposomal doxorubicin (LPs-DOX) and paclitaxel (LPs-PTX) via electrostatic force. Then we characterized the tbFGF-modified liposome (tbFGF-LPs) and examined internalization of doxorubicin in tumor cells (TRAMP-C1, B16) and HUVEC cells in vitro. In vivo, we evaluated the biodistribution and antitumor efficacy of tbFGF-LPs-DOX and tbFGF-LPs-PTX in C57BL/6J mice bearing TRAMP-C1 prostate carcinoma and B16 melanoma, respectively. The tbFGF-LPs-DOX significantly improved the uptake of doxorubicin in TRAMP-C1, B16 and HUVEC cells, respectively. Biodistribution study in B16 tumor-bearing mice showed that tbFGF-LPs-PTX achieved 7.1-fold (72.827+/-7.321mgh/L vs 10.292+/-0.775mgh/L, mean+/-SD, P<0.01) accumulation of paclitaxel in tumor tissue than those of free paclitaxel. More importantly, treatment of tumor-bearing mice with tbFGF-LPs-DOX and tbFGF-LPs-PTX showed the significant inhibition in tumor growth and improvement in survival rate as compared with mice treated with free and liposomal drugs in TRAMP-C1 and B16 tumor models, respectively. Furthermore, repeated intravenous administration of tbFGF-LPs-DOX/PTX did not induce anti-bFGF antibodies. These results suggested that this FGFR-mediated drug delivery system may provide a new treatment strategy for tumors which overexpress FGFRs.
2010 Elsevier B.V. All rights reserved.
Similar articles
- Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice.
Wang X, Deng L, Chen X, Pei H, Cai L, Zhao X, Wei Y, Chen L. Wang X, et al. J Pharm Sci. 2011 Mar;100(3):1196-205. doi: 10.1002/jps.22348. Epub 2010 Sep 21. J Pharm Sci. 2011. PMID: 20860011 - A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells.
Cai L, Qiu N, Li X, Luo K, Chen X, Yang L, He G, Wei Y, Chen L. Cai L, et al. Int J Pharm. 2011 Apr 15;408(1-2):173-82. doi: 10.1016/j.ijpharm.2011.01.042. Epub 2011 Jan 26. Int J Pharm. 2011. PMID: 21277964 - Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
Xiao W, Chen X, Yang L, Mao Y, Wei Y, Chen L. Xiao W, et al. Int J Pharm. 2010 Jun 30;393(1-2):119-26. doi: 10.1016/j.ijpharm.2010.04.018. Epub 2010 Apr 21. Int J Pharm. 2010. PMID: 20416367 - Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J, Metselaar JM, Storm G, van der Pluijm G. Kroon J, et al. Cancer Treat Rev. 2014 May;40(4):578-84. doi: 10.1016/j.ctrv.2013.10.005. Epub 2013 Oct 25. Cancer Treat Rev. 2014. PMID: 24216226 Review. - Bacterial ghosts (BGs)--advanced antigen and drug delivery system.
Kudela P, Koller VJ, Lubitz W. Kudela P, et al. Vaccine. 2010 Aug 16;28(36):5760-7. doi: 10.1016/j.vaccine.2010.06.087. Epub 2010 Jul 7. Vaccine. 2010. PMID: 20619379 Review.
Cited by
- Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
Cai L, Wang X, Wang W, Qiu N, Wen J, Duan X, Li X, Chen X, Yang L, Qian Z, Wei Y, Chen L. Cai L, et al. Int J Nanomedicine. 2012;7:4499-510. doi: 10.2147/IJN.S32817. Epub 2012 Aug 14. Int J Nanomedicine. 2012. PMID: 22923988 Free PMC article. - Optimization of Lipid Nanoformulations for Effective mRNA Delivery.
Chen H, Ren X, Xu S, Zhang D, Han T. Chen H, et al. Int J Nanomedicine. 2022 Jul 2;17:2893-2905. doi: 10.2147/IJN.S363990. eCollection 2022. Int J Nanomedicine. 2022. PMID: 35814615 Free PMC article. - Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo.
Li L, Yu C, Ren J, Ye S, Ou W, Wang Y, Yang W, Zhong G, Chen X, Shi H, Su X, Chen L, Zhu W. Li L, et al. J Cancer Res Clin Oncol. 2014 Jun;140(6):895-907. doi: 10.1007/s00432-014-1607-5. J Cancer Res Clin Oncol. 2014. PMID: 24659339 - Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity.
McNamara RP, Eason AB, Zhou Y, Bigi R, Griffith JD, Costantini LM, Rudek MA, Anders NM, Damania BA, Dittmer DP. McNamara RP, et al. ACS Bio Med Chem Au. 2022 Apr 20;2(2):140-149. doi: 10.1021/acsbiomedchemau.1c00030. Epub 2022 Jan 20. ACS Bio Med Chem Au. 2022. PMID: 35480227 Free PMC article. - Smart nanoparticles improve therapy for drug-resistant tumors by overcoming pathophysiological barriers.
Liu JP, Wang TT, Wang DG, Dong AJ, Li YP, Yu HJ. Liu JP, et al. Acta Pharmacol Sin. 2017 Jan;38(1):1-8. doi: 10.1038/aps.2016.84. Epub 2016 Aug 29. Acta Pharmacol Sin. 2017. PMID: 27569390 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical